Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.

Allergan PLC’s third quarter net revenues increased 4.4% year-over-year to $3.62bn, but the gain was $50m (1.5%) below analyst consensus estimates, since established brands lost more sales to generic medicines at a faster pace than expected. The legacy products’ new competition made the 2015 acquisition of blockbuster brand names Botox (onabotulinumtoxinA) and Restasis (cyclosporine) look like well-timed purchases.

Botox and Restasis instantly became the company’s top-selling products after Actavis acquired Allergan Inc. for $66bn in 2015....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

25 Jun 2025

• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

25 Jun 2025

• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

25 Jun 2025

• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

25 Jun 2025

• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.